Highly Active Myeloid Therapy for Cancer

Area of Science:

• Immunology
• Oncology
• Nanomedicine

Background:

• Tumor-associated macrophages (TAMs) play a crucial role in cancer progression by interacting with cancer and stromal cells.
• Targeting TAMs offers a promising strategy to improve cancer treatment outcomes and synergize with existing therapies like immunotherapy.
• Current knowledge gaps exist regarding optimal TAM pathway targeting and payload delivery for maximum antitumor effects.

Purpose of the Study:

• To investigate a multipart combination therapy targeting Janus tyrosine kinase (JAK), noncanonical nuclear factor kappa light chain enhancer of activated B cells (NF-κB), and toll-like receptor (TLR) pathways.
• To develop a highly active myeloid therapy (HAMT) for treating immunosuppressive tumor microenvironments.
• To identify drug combinations that maximize IL-12 production from myeloid cells for enhanced antitumor activity.

Main Methods:

• A drug screening approach was employed to identify optimal drug combinations for myeloid cell activation.
• A triple small-molecule combination was encapsulated within a TAM-targeted nanoparticle.
• The efficacy of the developed nanoparticle therapy was evaluated in murine cancer models.

Main Results:

• The triple small-molecule combination nanoparticle demonstrated extraordinary efficacy in eradicating murine tumors.
• The therapy successfully reprogrammed TAMs to an antitumor phenotype, initiating a potent antitumor immune response.
• The HAMT approach showed significant synergy with other immunotherapies, leading to durable responses in preclinical models.

Conclusions:

• The developed HAMT represents a novel and effective immunotherapy approach for cancer treatment.
• Targeting JAK, NF-κB, and TLR pathways simultaneously via nanoparticles can overcome tumor immunosuppression.
• This strategy holds potential for improving clinical outcomes in various cancer types through enhanced antitumor immunity.